Determination of immunological biomarkers in sarcoidosis and their relation to disease activity
|The Egyptian Journal of Immunology
Volume 30 (3), July, 2023
Pages: 92 – 101.
|Radwa S. Ibrahim1, Asmaa S. Hassan1, Eman M. Moazen2, and Eman K. Mohamed3|
|1Department of Clinical Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
2Department of Chest, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
3Department of Blood Bank, Al Haram Hospital, Specialized Medical Centers, Giza, Egypt.
Eman K. Mohamed, Department of Blood Bank, Al Haram Hospital, Specialized Medical Centers, Giza, Egypt.
Sarcoidosis is a multisystem granulomatous disease of unknown origin. Ninety percent of patients with sarcoidosis have lung involvement. The onset can be acute or non-acute and the severity of sarcoidosis ranges widely from asymptomatic patients with accidental radiographic findings to patients with severe organ involvement. This case control analytic prospective study was conducted at the Chest Clinic, Al Zahraa hospital, to assess the diagnostic value of serum soluble interleukin 2 receptor (sIL-2R), cluster of differentiation 4 (CD4)/CD8 ratio and CD103 in sarcoidosis. We investigated the value of serum sIL-2R using ELISA and blood CD103, blood CD4/CD8 ratio using flow cytometry for 30 cases of sarcoidosis in different stages and 30 control persons to detect their use as a marker for diagnosis. We found a significant increase in sIL-2R in the sarcoidosis group as compared to the control group (p˂0.0001), while there was a significant decrease in CD103/CD4 in sarcoidosis group as compared to the control group (p <0.001). In conclusion, sIL-2R and CD103 can be used as diagnostic markers for sarcoidosis.
Sarcoidosis, sIL-2R, CD103, CD4/CD8 ratio.
01 February 2023; accepted: 10 May 2023